Table 3 Canonical pathways significant in nonmetastatic prostate cancer to metastatic prostate cancer transition identified by Ingenuity*

Tight junction signaling

3.37

IGF-1 signaling

2.68

Integrin signaling

2.33

ERK/MAPK signaling

2.32

Regulation of actin-based motility by Rho

2.22

Hepatic fibrosis/hepatic stellate cell activation

2.14

Cardiac beta²-adrenergic signaling

1.92

EGF signaling

1.86

Actin cytoskeleton signaling

1.84

PPARα/RXRα activation

1.72

IL-4 signaling

1.71

Nitric oxide signaling in the cardiovascular system

1.62

Hypoxia signaling in the cardiovascular system

1.62

Antigen presentation pathway

1.51

Glucocorticoid receptor signaling

1.46

Glycolysis/gluconeogenesis

1.40

TGF-beta signaling

1.36